Anti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages From Cystic Fibrosis Abdullah A Tarique, Tama Evron, George Zhang, Mark A Tepper, Mohammed M Morshed, Isabella S G Andersen, Nelufa Begum, Peter D Sly, Emmanuelle Fantino Journal of Cystic Fibrosis, 2020, S1569-1993, (20), 30094-1 doi : 10.1016/j.jcf.2020.03.015. Abstract Background : Lenabasum is an oral synthetic cannabinoid receptor type 2 agonist previously shown to reduce the production of key airway pro-inflammatory cytokines known to play a role in cystic fibrosis (CF). In a double-blinded, randomized, placebo-control phase 2 study, lenabasum lowered the rate of pulmonary exacerbation among patients with CF. The present study was undertaken to investigate anti-inflammatory [...]
Lire la suite